CliffBio
small molecule

SAMSCA

TOLVAPTAN

Loss of exclusivityApril 2030latest FDA-listed patent expiry
CompanyOtsuka Pharmaceutical →View the full company profile on CliffBio

Drug detail

Brand nameSAMSCA
Active ingredientTOLVAPTAN
Strength60MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMay 2009
Marketing statusDISCN

Listed patents

PatentExpiresType
10905694April 2030product
8501730September 2026substance

More from Otsuka Pharmaceutical

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SAMSCA patent cliff — loss of exclusivity April 2030 | CliffBio